Cargando…
Targeting USP13‐mediated drug tolerance increases the efficacy of EGFR inhibition of mutant EGFR in non‐small cell lung cancer
In non‐small cell lung cancer (NSCLC), activating mutations in the epidermal growth factor receptor (EGFR) induce sensitivity to EGFR tyrosine kinase inhibitors. Despite impressive clinical responses, patients ultimately relapse as a reservoir of drug‐tolerant cells persist, which ultimately leads t...
Autores principales: | Giron, Philippe, Eggermont, Carolien, Noeparast, Amir, Vandenplas, Hugo, Teugels, Erik, Forsyth, Ramses, De Wever, Olivier, Aza‐Blanc, Pedro, Gutierrez, Gustavo J., De Grève, Jacques |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048518/ https://www.ncbi.nlm.nih.gov/pubmed/33210294 http://dx.doi.org/10.1002/ijc.33404 |
Ejemplares similares
-
The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer
por: Eggermont, Carolien, et al.
Publicado: (2022) -
Inhibition of PLK1 Destabilizes EGFR and Sensitizes EGFR-Mutated Lung Cancer Cells to Small Molecule Inhibitor Osimertinib
por: Eggermont, Carolien, et al.
Publicado: (2023) -
Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer
por: Noeparast, Amir, et al.
Publicado: (2018) -
Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer
por: Umelo, Ijeoma, et al.
Publicado: (2015) -
CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition
por: Noeparast, Amir, et al.
Publicado: (2019)